Snowball Research

Snowball Research

Share this post

Snowball Research
Snowball Research
Whitefort Capital Management urges Arbutus Biopharma Corporation (ABUS) to explore Strategic actions
Copy link
Facebook
Email
Notes
More

Whitefort Capital Management urges Arbutus Biopharma Corporation (ABUS) to explore Strategic actions

May 10, 2024
∙ Paid

Share this post

Snowball Research
Snowball Research
Whitefort Capital Management urges Arbutus Biopharma Corporation (ABUS) to explore Strategic actions
Copy link
Facebook
Email
Notes
More
Share
Key Summary: On May 9, 2024, Whitefort Capital Management (6.8%) urged the Board to enhance the company's value by ending the ATM program and exploring HBV portfolio options.

Market Cap: $554 million | Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States…

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Snowball Research | March Intelligence Research LLP
Publisher Terms
Substack
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More